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Abstract
Background: Maintainance of a stable basal insulin level is important for glycemic control in treatment of diabetes
mellitus. Recently introduced insulin degludec has the longest duration of action among basal insulin formulations. The
purpose of this study was to assess changes in quality of life (QOL) associated with switching the basal insulin regimen
to degludec in patients with type 1 and type 2 diabetes mellitus.
Methods: This 24-week open-label intervention study included type 1 (n = 10) and type 2 (n = 20) diabetes mellitus
patients, with adequately controlled hemoglobin A1c (HbA1c), who had received insulin glargine or detemir for at least
6 months. The primary outcome was change of QOL from baseline, as assessed by the Diabetes Therapy-Related QOL
(DTR-QOL) application, after switching from glargine or detemir to degludec. HbA1c and other parameters were also
assessed as secondary outcomes.
Results: QOL and HbA1c in patients with type 1 diabetes mellitus were unchanged during this study. In patients with
type 2 diabetes mellitus, HbA1c did not change, but total DTR-QOL score was significantly improved from baseline
after switching to degludec. The DTR-QOL Factor 2, “Anxiety and dissatisfaction with treatment”, was significantly
improved in patients with type 2 diabetes mellitus and especially in the subgroup receiving basal supported oral
therapy (BOT).
Conclusions: Switching of the basal insulin regimen from glargine or detemir to degludec significantly improved the
QOL of patients with type 2 diabetes mellitus who were receiving BOT, by reducing mental stress or anxiety about
their treatment.
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Background
Strict glycemic control is important for prevention of
diabetic complications in patients with type 1 and type
2 diabetes mellitus. However, insulin therapies often
have adverse effects on quality of life (QOL). Most
patients with type 1 diabetes mellitus receive intensive
insulin therapy. On the other hand, for patients with
type 2 diabetes mellitus, basal supported oral therapy
(BOT), consisting of basal insulin injection and an oral
hypoglycemic agent, is widely used. Thus, long-acting
insulin preparations play an important role in both
types of patients. Three types of long-acting insulin are
currently available, i.e., glargine, detemir, and degludec,
which were introduced in 2000, 2002, and 2013, respect-
ively. The duration of action of glargine is 27 h (range:
10.5–29.0) and that of detemir is 23 h (range: 4.0–30.0)
[1], whereas degludec has a duration of action greater than
40 h, with a terminal half-life of more than 25 h [2].
Degludec is a slightly modified insulin that forms stable
multi-hexamers; after injection of the preparation under
subcutaneous tissue, monomeric degludec dissociates
slowly from the ends of the multi-hexamers, resulting in a
very long duration of action [3]. Degludec showed similar
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efficacy to glargine or detemir in terms of hemoglobin
A1c (HbA1c) level and significantly reduced the risk of
hypoglycemia during the night in both type 1 and type 2
diabetes mellitus patients in a large clinical trial, which
included Japanese patients [4–6].
Despite the advantages of degludec, its effects on patients’
QOL have not yet been reported. In this work, we exam-
ined the change in QOL associated with a switch in basal
insulin regimen from glargine or detemir to degludec in
patients with type 1 and type 2 diabetes mellitus.
Methods
Study design and participants
Ten outpatients with type 1 and 20 outpatients with type
2 diabetes mellitus, who had not previously been treated
with insulin degludec, were included in this prospective
study at the Japan Community Healthcare Organization
Kanazawa Hospital. The main inclusion criteria were
age ≥ 20 years, diagnosis of type 1 or type 2 diabetes,
treatment with glargine or detemir for at least 24 weeks
before entry into this study, and less than 1.0 % HbA1c
change during the 24 weeks before entry into this
study. When we switched to degludec, injection was
given once a day regardless of the number of injections
(once or twice a day) of basal insulin. Written informed
consent was obtained from each participant before any
survey was carried out. Any patient who could not
understand the QOL questionnaire was dropped from
the study.
This study is a registered clinical study, number 13-02-
01, and was conducted in accordance with the Declaration
of Helsinki and Good Clinical Practice Guidelines. The
protocol and the consent form were reviewed and ap-
proved by the local independent ethics committee of Japan
Community Healthcare Organization, Kanazawa Hospital,
before initiation of the study.
Study objectives
Patient QOL was the primary outcome. All patients were
evaluated using the Diabetes Therapy-Related QOL (DTR-
QOL) scoring application (for iPad) developed by Ishii [7].
Patient-reported outcomes are divided into 4 factors: (1)
Burden on social activities and daily activities, (2) Anxiety
and dissatisfaction with treatment, (3) Hypoglycemia, and
(4) Satisfaction with treatment. Factors 1, 2, 3, and 4 consist
of 13, 8, 4, and 4 items, respectively (Table 1). The score of
each item is rated using a 7-point Likert scale (1 is strongly
agree, 7 is strongly disagree). The scores are converted to a
range of 0–100, and the application automatically computes
a total score. The DTR-QOL score correlates moderately
well with Diabetes Treatment Satisfaction Questionnaire
and MOS 8-Item Short-Form Health Survey scores [7]. In
this study, we measured the DTR-QOL at baseline, and
after 12 and 24 weeks of therapy with degludec.
Table 1 DTR-QOL items and domain structure
Factor 1: Burden on social activities and daily activities
1. My current diabetes treatment interferes with my work and activities.
2. My current diabetes treatment limits the scope of my activities.
3. It is difficult to find places on time for my current diabetes.
4. My current diabetes treatment interferes with group activities and
personal friendships.
5. It is a burden getting up at a certain time every morning for my
current diabetes treatment.
6. With my current diabetes treatment, the restricted meal times are a
burden.
7. When I eat out, it is difficult to manage my current diabetes
treatment.
8. I feel like my current diabetes treatment takes away the enjoyment
of eating.
9. With my current diabetes treatment, it is hard to curb my appetite.
10. The time and effort to manage my current diabetes treatment are
a burden.
11. I am constantly concerned about time to manage my current
diabetes treatment.
12. Pain due to my current diabetes treatment is uncomfortable.
13. Gastrointestinal symptoms (nausea, passing gas, diarrhea,
abdominal pain) due my current diabetes treatment are
uncomfortable.
Factor 2: Anxiety and dissatisfaction with treatment
14. I am bothered by weight gain with my current diabetes treatment.
19. I have uncomfortable symptoms due to hyperglycemia (high
blood glucose).
20. I am worried about high blood glucose.
21. I am dissatisfied that my blood glucose is unstable (high and low).
22. I am worried that complications might get worse with my current
diabetes treatment.
23. I get anxious thinking about living while on my current diabetes
treatment.
24. I find it unbearable to think that even if I continue my current
diabetes treatment, my diabetes may not be cured.
25. I am concerned that if I continue my current diabetes treatment,
the efficacy (effectiveness) may diminish.
Factor 3: Hypoglycemia
15. I worry about low blood glucose due to my current diabetes
treatment.
16. I am scared because of low blood glucose.
17. I am sometimes bothered by low blood glucose.
18. Symptoms due to low blood glucose are uncomfortable.
Factor 4: Satisfaction with treatment
26. Overall, I am satisfied with my current blood sugar control
(glycemic control).
27. With my current diabetes treatment, I am confident that I can
maintain good blood glucose control.
28. I am hopeful about the future with my current diabetes treatment.
29. With regards to diabetes treatment, I am satisfied with current
treatment methods.
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Secondary outcomes included HbA1c, which was mea-
sured every 4 weeks and expressed as National Glycohe
moglobin Standardization Program equivalent values [8].
Fasting blood glucose (FBG), 1,5-anhydroglucitol (1,5-
AG), amount of insulin units taken and body weight
were also evaluated at baseline and after 12 and 24 weeks
of therapy. Baseline clinical characteristics of patients in-
corporated in this study were age, sex, body mass index
(BMI), duration of diabetes mellitus, HbA1c, and prior
insulin treatment, including oral hypoglycemic agents
and frequency of injections (Table 2). In principle, the
regimen was kept unchanged during this study.
Statistical analysis
All data were analyzed using IBM SPSS statistical software
version 18 for Windows (SPSS Japan Inc., Tokyo, Japan).
One-way analysis of variance (ANOVA) was used for
comparisons of numerical values (DTR-QOL score, each
item score, HbA1c, FBG, 1,5-AG, body weight and
amount of insulin units between baseline and after treat-
ment with degludec). Data were expressed as the mean ±
standard deviation. P values under 5 % were considered to
be significant.
Results
Changes of QOL after switching to degludec
As shown in Fig. 1, patients with type 2 diabetes mellitus
had higher total DTR-QOL scores than patients with type
1 diabetes mellitus throughout this study (baseline, 54.8 ±
11.3 points vs. 44.6 ± 11.6 points, p < 0.05; at 12 weeks,
60.7 ± 12.0 points vs. 43.8 ± 12.0 points, p < 0.005; at
24 weeks, 59.0 ± 12.9 points vs. 48.3 ± 11.2 points, p <
0.05). However, the DTR-QOL scores of patients with type
1 diabetes mellitus showed no significant change during
degludec treatment (Fig. 1 (a)). On the other hand, the
total DTR-QOL scores of patients with type 2 diabetes
mellitus showed significant improvement (baseline, 54.8 ±
11.3 points; 12 weeks, 60.7 ± 12.0 points; 24 weeks, 59.0 ±
12.9 points; p < 0.05), as shown in Fig. 1 (b). Further, the
DTR-QOL Factor 2 “Anxiety and dissatisfaction with
treatment” subscale score was significantly improved in
patients with type 2 diabetes mellitus at weeks 12 and 24
compared to baseline (baseline, 42.5 ± 18.0 points;
12 weeks, 52.5 ± 17.0 points; 24 weeks, 52.7 ± 14.0 points;
p < 0.005) (Fig. 1 (b)).
Among the items within Factor 2, a significant improve-
ment from baseline was seen in the score of item No. 23
Table 2 Baseline clinical characteristics of participants
Items Type 1 Type 2
Number (male/female) 10 (5/5) 20 (11/9)
Age (years) 52.1 ± 15.3 61.9 ± 13.1
BMI (kg/m2) 22.2 ± 2.7 24.7 ± 4.8
Duration of diabetes (years) 7.5 ± 4.2 14.6 ± 7.6
HbA1c (%) 8.2 ± 1.4 7.6 ± 1.2
Prior treatment insulin
Insulin glargine 8 (80 %) 13 (65 %)
Insulin detemir 2 (20 %) 7 (35 %)
Bolus insulin 10 (100 %) 7 (35 %)
The frequency of injections with basal insulin before switching
Once 3 (30 %) 13 (65 %)
Twice 7 (70 %) 7 (35 %)
Other concomitant drugs
Glucagon like peptide-1 receptor agonist 0 (0 %) 0 (0 %)
Sulphonylurea 0 (0 %) 2 (10 %)
Glinide 0 (0 %) 7 (35 %)
Metformin 0 (0 %) 10 (50 %)
Pioglitazone 0 (0 %) 2 (10 %)
α-glucosidase inhibitor 0 (0 %) 5 (25 %)
Dipeptidyl peptidase 4 inhibitor 0 (0 %) 8 (40 %)











































































Fig. 1 Changes of Factor and total scores in type 1 and type 2
diabetes mellitus. The upper figure (a) showed the type 1, the lower
figure (b) shows the type 2 patients after switching from glargine or
detemir to degludec. Grey, white, and dark columns indicate scores
at baseline, 12 weeks, and 24 weeks, respectively. Data are mean ±
SD (bars) for all assigned participants. Comparisons were made by
ANOVA. * p < 0.05, ** p < 0.005, significantly different from baseline
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“I get anxious thinking about living while on my
current diabetes treatment” (baseline, 2.8 ± 1.4 points;
12 weeks, 4.0 ± 1.9 points; 24 weeks, 3.9 ± 1.5 points;
p < 0.005) (Fig. 2).
When we divided patients with type 2 diabetes mellitus
into subgroups according to treatment, those who were
receiving BOT (n = 13) showed significantly increased
DTR-QOL scores (baseline, 54.3 ± 10.7 points; 12 weeks,
61.4 ± 11.1 points; 24 weeks, 60.2 ± 12.9 points; p < 0.05),
whereas other patients (n = 7) did not (Fig. 3). Their Factor
2 scores were also significantly increased (baseline, 41.7 ±
18.0 points; 12 weeks, 54.7 ± 17.3 points; 24 weeks, 55.8 ±
14.1 points; p < 0.005) (Fig. 3). Moreover, their scores of
item No. 23 showed significant improvement (baseline,
2.7 ± 1.4 points; 12 weeks, 4.1 ± 1.8 points; 24 weeks, 4.2 ±
1.7 points; p < 0.005).
Glycemic control
FBG, 1.5-AG and HbA1c showed no significant change in
either type 1 or type 2 diabetes mellitus patients during
the study (Table 3 and Fig. 4).
Change in number of insulin units
The total number of bolus insulin units taken by patients
with type 1 and type 2 diabetes mellitus did not change
during the study (20.3 ± 6.5 units and 19.9 ± 5.7 units at
baseline to 19.4 ± 7.1 units and 20.1 ± 5.5 units at week 12,
19.0 ± 7.3 units and 20.0 ± 5.6 units at week 24, respect-
ively). However, the total number of basal insulin units in
patients with type 1 and type 2 diabetes mellitus decreased
significantly from 14.4 ± 5.1 unit and 13.4 ± 7.6 unit at base-
line to 12.3 ± 5.0 unit and 11.9 ± 6.7 unit at 12 weeks, and to 12.3 ± 6.1 unit and 11.4 ± 6.3 unit at 24 weeks, respect-
ively (Table 3).
Change of body weight
Switching the basal insulin regimen to degludec had no



































Fig. 2 Changes of item scores in Factor 2 in patients with type 2
diabetes mellitus. Grey, white, and dark columns indicate item scores
in Factor 2 at baseline, 12 weeks, and 24 weeks, respectively. Data
are mean ± SD (bars) for all assigned participants. Comparisons were

































































Fig. 3 Changes of Factor and total scores in type 2 diabetes mellitus
according to insulin treatment. The upper figure (a) shows the receiving
multiple insulin therapy, the lower figure (b) shows the receiving BOT on
type 2 patients. Grey, white, and dark columns indicate DTR-QOL score at
baseline, 12 weeks, and 24 weeks, respectively. Data are mean ± SD (bars)
for all assigned participants. Comparisons were made by ANOVA.
* p< 0.05, ** p< 0.005, significantly different from baseline
Table 3 Change of secondary outcomes in participants
Term Type Baseline 12 weeks 24 weeks
FBG (mg/dL) 1 160.8 ± 68.7 150.2 ± 37.4 149.4 ± 46.7
2 152.9 ± 61.5 141.1 ± 50.0 142.1 ± 51.5
1.5-AG (μg/mL) 1 6.9 ± 5.5 7.8 ± 6.5 9.7 ± 8.8
2 8.0 ± 4.9 10.4 ± 7.2 10.4 ± 5.5
Bolus insulin (IU/day) 1 20.3 ± 6.5 19.4 ± 7.1 19.0 ± 7.3
2 19.9 ± 5.7 20.1 ± 5.5 20.0 ± 5.6
Basal insulin (IU/day) 1 14.4 ± 5.1 12.3 ± 5.0 * 12.3 ± 6.1 *
2 13.4 ± 7.6 11.9 ± 6.7 * 11.4 ± 6.3 *
Body weight (kg) 1 58.7 ± 11.4 57.9 ± 10.8 57.5 ± 11.1
2 66.6 ± 14.7 66.8 ± 14.7 66.9 ± 14.6
Data are mean ± SD. Comparisons were made by ANOVA. * p < 0.05,
significantly different from baseline
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type 1 diabetes mellitus (58.7 ± 11.4 kg at baseline to
57.9 ± 10.8 kg at 12 weeks and 57.5 ± 11.1 kg at 24 weeks)
or type 2 diabetes mellitus (66.6 ± 14.7 kg at baseline to
66.8 ± 14.7 kg at week 12 and 66.9 ± 14.6 kg at week 24)
(Table 3).
Occurrence of hypoglycemia
None of the patients with either type 1 or type 2 diabetes
mellitus experienced serious hypoglycemia or reported
blood sugar levels below 60 mg/dL (measured by self-
monitoring).
Discussion
Our results indicate that switching from glargine or detemir
to degludec resulted in a significant improvement of the
DTR-QOL score in patients with type 2 diabetes mellitus,
but not in those with type 1 diabetes mellitus. DTR-QOL
scores are associated with the levels of self-care activities
[9], and we found that our type 2 patients showed a signifi-
cant improvement in the score for Factor 2, “Anxiety and
dissatisfaction with treatment”, which includes items deal-
ing with weight gain, discomfort, anxiety, and dissatisfac-
tion with treatment (Table 1). Specifically, we found a
significant improvement in the score for item No. 23 “I get
anxious thinking about living while on my current diabetes
treatment”.
Previous reports have identified glycemic control, type
of insulin therapy, and frequency of hypoglycemia as
factors influencing QOL [9]. Therefore, we investigated
the influence of these factors in our patients. Firstly,
regarding glycemic control, HbA1c was measured every
4 weeks during the 24-week study, and we found no
significant change in either type 1 or type 2 patients, in
agreement with previous reports [4–6]. Further, there was
no significant change in items related to hyperglycemia in
Factor 2 of the DTR-QOL. These results suggest that the
improvement of QOL cannot be explained in terms of
lowering of HbA1c.
Secondly we investigated the relation between QOL and
insulin treatment. Basal insulin units were decreased signifi-
cantly in patients with both type 1 and type 2 diabetes mel-
litus (Table 3), but improvement of QOL was seen only in
patients with type 2 diabetes mellitus, not in patients with
type 1, suggesting that the decrease of insulin units cannot
explain the improvement of QOL. It should be noted that 7
out of 10 patients with type 1 diabetes mellitus had received
two injections of basal insulin and 3 injections of bolus
insulin per day (total, 5 injections) during treatment with
glargine or detemir, while switching to degludec reduced
the number of basal injections to one (total, 4 injections).
Glycemic control was well maintained, but it appeared that
the reduction of injection frequency from 5 times to 4
times was not sufficient to significantly improve QOL of
these patients. In the case of patients with type 2 diabetes
mellitus, the number of injections per day remained the
same after switching to degludec, even though the switch
to degludec significantly improved QOL. Interestingly, sub-
group analysis according to type of treatment revealed a
significant QOL improvement in patients receiving BOT
(13 out of 20 patients) (Fig. 3). There was no significant dif-
ference in the clinical background between patients receiv-
ing BOT and other patients with type 2 diabetes mellitus.
These results suggest that the key factor for QOL improve-
ment is the difference of corrective action if an injection is
forgotten. For pharmacokinetic reasons [10], doctors at our
hospital advise that if patients with type 1 and type 2
diabetes mellitus forget to take an injection of glargine or
detemir for more than 2 h after the scheduled time, they
should not self-medicate to avoid hypoglycemia, but should
contact their doctors to ask for instructions. On the other
hand, if patients taking degludec forget an injection, they
can take it when they remember, and then take the next
injection at least eight hours later, since the daily injection
time of degludec can be varied without compromising
glycemic control or safety because of its long duration of
action [11]. This flexibility may be especially beneficial in
BOT therapy, since degludec can be injected at the patient’s
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Fig. 4 Time course of HbA1c in type 1 and type 2 diabetes mellitus
patients. (a) HbA1c in type 1 patients (●) and (b) HbA1c in type 2
patients (▲) after switching from glargine or detemir to degludec. Data
are mean ± SD (bars) for all assigned participants. Comparisons were
made by ANOVA
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of QOL in type 2 patients was due to a decrease of mental
stress associated with treatment, because of the flexibility in
timing of degludec injection. This is consistent with the
improvement in the score of item No. 23 in Factor 2 of the
DTR-QOL (“I get anxious thinking about living while on
my current diabetes treatment”). The validity of the im-
provement in the score of item No. 23 is also supported
by the observation of improvements of 0.3–0.8 points
from baseline in the score of items No.1, No.2, No.3,
No.6, No.7 and No.11 in Factor 1 of the DTR-QOL,
though these did not reach statistical significance. On
the other hand, patients with type 1 diabetes mellitus
are well aware that insulin therapy is essential for life
support, and basal insulin is often administered simultan-
eously with bolus insulin, so these patients may not feel the
benefits of flexible injection of degludec.
Finally, we found no improvement of Factor 3,
“Hypoglycemia” in this study, even though degludec
is reported to significantly reduce the frequency of
hypoglycemia during the night, compared to glargine
or detemir [4–6]. The reason for this may be that
our target patients had not experienced hypoglycemia
while receiving glargine or detemir, and also did not
experience it after switching to degludec, so that
there was no change of QOL in this respect.
The present study has several limitations. The number of
cases was small, because this research was performed at a
single site. Also, this exploratory study used an open label
design. Further, insulin degludec was administered with a
new device, Flextouch® [12–14]. There were differing
opinions, both positive and negative, about the new device
in our survey. In the future, we need to clarify the influence
of the delivery device of insulin therapy on QOL.
Conclusions
An important finding in our study was that switching to
degludec from glargine or detemir in patients with type 2
diabetes mellitus, especially those who were receiving
BOT, improved the QOL, even though there was no
significant change of HbA1c. This improvement of QOL
may be attributed to a reduction of mental stress and
anxiety due to the greater flexibility of treatment timing
with degludec.
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